Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 19% Improvement Relative Risk Improvement 74% Time to improvement 29% Hospitalization time 31% Sarhan et al. NCT04738760 Vitamin D RCT LATE TREATMENT Is late treatment with vitamin D beneficial for COVID-19? RCT 116 patients in Egypt (December 2020 - June 2021) Lower mortality (p=0.003) and greater improvement (p=0.03) Sarhan et al., Medicina, doi:10.3390/medicina58101358 Favors high dose Favors low dose
Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe COVID-19 Patients: A Randomized Clinical Trial
Sarhan et al., Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe.., Medicina, doi:10.3390/medicina58101358, NCT04738760
Sep 2022   Source   PDF  
  All Studies   Meta
RCT comparing 200,000IU IM cholecalciferol and 1mcg/day alfacalcidol, showing lower mortality and improved recovery with high dose treatment.
risk of death, 18.5% lower, RR 0.81, p = 0.003, treatment 26 of 58 (44.8%), control 30 of 58 (51.7%), NNT 14, adjusted per study, odds ratio converted to relative risk, multivariable.
improvement, 74.4% better, OR 0.26, p = 0.03, treatment 58, control 58, adjusted per study, inverted to make OR<1 favor treatment, multivariable, RR approximated with OR.
time to improvement, 28.8% lower, relative time 0.71, p = 0.002, treatment 58, control 58.
hospitalization time, 31.5% lower, relative time 0.69, p = 0.04, treatment 58, control 58.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sarhan et al., 27 Sep 2022, Randomized Controlled Trial, Egypt, peer-reviewed, 9 authors, study period December 2020 - June 2021, dosage 200,000IU single dose, trial NCT04738760 (history).
Contact: (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: medicina Article Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe COVID-19 Patients: A Randomized Clinical Trial Neven Sarhan 1 , Ahmed E. Abou Warda 2 , Rania M. Sarhan 3 , Marian S. Boshra 3 , Gomaa Mostafa-Hedeab 4, * , Bashayer F. ALruwaili 5 , Haytham Soliman Ghareeb Ibrahim 6 , Mona F. Schaalan 1 and Shaimaa Fathy 1 1 2 3 4 5 6 * Citation: Sarhan, N.; Abou Warda, A.E.; Sarhan, R.M.; Boshra, M.S.; Mostafa-Hedeab, G.; ALruwaili, B.F.; Ibrahim, H.S.G.; Schaalan, M.F.; Fathy, S. Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe COVID-19 Patients: A Randomized Clinical Trial. Medicina 2022, 58, 1358. medicina58101358 Academic Editor: Silvia Angeletti Received: 14 September 2022 Accepted: 20 September 2022 Published: 27 September 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in Clinical Pharmacy Department, Faculty of Pharmacy, Misr International University, Cairo 11828, Egypt Clinical Pharmacy Department, Faculty of Pharmacy, October 6 University, P.O. Box 12585, Giza 12585, Egypt Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, P.O. Box 62514, Beni-Suef 62511, Egypt Pharmacology Department, Medical College, Jouf University, Sakaka 72388, Saudi Arabia Community and Family Medicine Department, Division of Family Medicine, Medical College, Jouf University, Sakaka 72388, Saudi Arabia Cardiology Department, Faculty of Medicine, El-Fayoum University, P.O. Box 63514, El Fayoum 63511, Egypt Correspondence:; Tel.: +966-5346-2739 Abstract: Background and Objectives: Vitamin D supplementation plays a key effect in lowering cytokine storms among COVID-19 patients by influencing the activity of the renin-angiotensin system and the production of the angiotensin-2 converting enzyme. The study was conducted to explore the effect of high-dose intramuscular vitamin D in hospitalized adults infected with moderate-tosevere SARS-CoV-2 in comparison with the standard of care in the COVID-19 protocol. Materials and Methods: Two groups of patients were compared in this prospective randomized controlled trial as the vitamin D was administered orally to group 1 (alfacalcidol 1 mcg/day) and intramuscularly to group 2 (cholecalciferol 200,000 IU). One hundred and sixteen participants were recruited in total, with fifty-eight patients in each group. Following the Egyptian Ministry of Health’s policy for COVID-19 management, all patients received the same treatment for a minimum of five days. Results: A significant difference was recorded in the length of hospital stay (8.6 versus 6.8 days), need for high oxygen or non-invasive mechanical ventilator (67% versus 33%), need for a mechanical ventilator (25% versus 75%), clinical improvement (45% versus 55%), the occurrence of sepsis (35% versus 65%), and in the monitored laboratory parameters in favor of high-dose vitamin D. Moreover, clinical improvement was significantly associated with the need for low/high oxygen, an invasive/noninvasive mechanical ventilator (MV/NIMV), and diabetes, while mortality was associated with the need for MV, ICU admission, atrial fibrillation, chronic obstructive pulmonary disease, asthma, and the occurrence of secondary infection. Conclusions: Our study showed that high-dose vitamin D was considered a promising treatment in the suppression of cytokine storms among..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop